Century Therapeutics Inc. (IPSC)
NASDAQ: IPSCHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IPSC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $231.78M
- EPS (TTM)
- -$0.91
- Dividend yield
- None
- 52-week range
- 0.435 – 3.04
- Day range
- 1.27 – 1.32
- Volume / Avg
- 697.24K / 658.60K
- Beta
- —
- Shares outstanding
- 181.08M
52-week range
IPSC stock today
Century Therapeutics (IPSC) closed at $1.28 on Oct 7, down 3.03% (-$0.04), versus the S&P 500's 0.22% decline. Shares are 57.9% below their 52-week high of $3.04, set on Mar 10, 2026 and 194.3% above the 52-week low of $0.435, in the middle of the past year's range. IPSC is up 28.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 129.0%.
Century Therapeutics has posted a net loss over the last twelve months (EPS of -$0.91), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Century Therapeutics
Company profileCentury Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
- Headquarters
- Philadelphia, PA
- Employees
- 78
- IPO year
- 2021
- Website
- centurytx.com
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$4.75+271.09%
- Strong buy 1
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Century Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRQRProQR Therapeutics N.V. | 1.63 | -1.21% | $230.02M | vs IPSC |
| IFRXInflaRx N.V. | 1.56 | -1.27% | $229.89M | vs IPSC |
| SLGLSol-Gel Technologies Ltd. | 71.95 | -4.88% | $235.55M | vs IPSC |
| MGNXMacroGenics Inc. | 3.55 | -2.47% | $226.14M | vs IPSC |
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs IPSC |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs IPSC |
| QTTBQ32 Bio Inc. | 7.99 | -1.48% | $237.86M | vs IPSC |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs IPSC |
Indexes, lists and sector
Appears in lists
Century Therapeutics stock FAQ
What is Century Therapeutics's stock price today?
IPSC last traded at $1.28 as of Oct 7, 4:00 PM EDT, down 3.03% on the day. Prices are delayed at least 15 minutes.
Who is Century Therapeutics's CEO?
Dr. Brent Pfeiffenberger M.B.A., Pharm.D. is the chief executive officer of Century Therapeutics Inc., which has about 78 employees.
What is the IPSC 52-week high?
The 52-week high for IPSC is $3.04 and the 52-week low is $0.435. The stock is currently 57.9% below its high.